ZikaPLAN: addressing the knowledge gaps and working towards a research preparedness network in the Americas by Wilder-Smith, A. (Annelies) et al.
Global Health Action
ISSN: 1654-9716 (Print) 1654-9880 (Online) Journal homepage: https://www.tandfonline.com/loi/zgha20
ZikaPLAN: addressing the knowledge gaps and
working towards a research preparedness network
in the Americas
Annelies Wilder-Smith, Raman Preet, Elizabeth B. Brickley, Ricardo Arraes de
Alencar Ximenes, Demócrito de Barros Miranda-Filho, Celina Maria Turchi
Martelli, Thália Velho Barreto de Araújo, Ulisses Ramos Montarroyos, Maria
Elisabeth Moreira, Marília Dalva Turchi, Tom Solomon, Bart C. Jacobs, Carlos
Pardo Villamizar, Lyda Osorio, Ana Maria Bispo de Filipps, Johan Neyts,
Suzanne Kaptein, Ralph Huits, Kevin K. Ariën, Hugh J. Willison, Julia M. Edgar,
Susan C. Barnett, Rosanna Peeling, Debi Boeras, Maria G. Guzman, Aravinda
M. de Silva, Andrew K. Falconar, Claudia Romero-Vivas, Michael W. Gaunt,
Alessandro Sette, Daniela Weiskopf, Louis Lambrechts, Helen Dolk, Joan
K. Morris, Ieda M. Orioli, Kathleen M. O’Reilly, Laith Yakob, Joacim Rocklöv,
Cristiane Soares, Maria Lúcia Brito Ferreira, Rafael Freitas de Oliveira
Franca, Alexander R. Precioso, James Logan, Trudie Lang, Nina Jamieson &
Eduardo Massad
To cite this article: Annelies Wilder-Smith, Raman Preet, Elizabeth B. Brickley, Ricardo Arraes de
Alencar Ximenes, Demócrito de Barros Miranda-Filho, Celina Maria Turchi Martelli, Thália Velho
Barreto de Araújo, Ulisses Ramos Montarroyos, Maria Elisabeth Moreira, Marília Dalva Turchi, Tom
Solomon, Bart C. Jacobs, Carlos Pardo Villamizar, Lyda Osorio, Ana Maria Bispo de Filipps, Johan
Neyts, Suzanne Kaptein, Ralph Huits, Kevin K. Ariën, Hugh J. Willison, Julia M. Edgar, Susan
C. Barnett, Rosanna Peeling, Debi Boeras, Maria G. Guzman, Aravinda M. de Silva, Andrew K.
Falconar, Claudia Romero-Vivas, Michael W. Gaunt, Alessandro Sette, Daniela Weiskopf, Louis
Lambrechts, Helen Dolk, Joan K. Morris, Ieda M. Orioli, Kathleen M. O’Reilly, Laith Yakob, Joacim
Rocklöv, Cristiane Soares, Maria Lúcia Brito Ferreira, Rafael Freitas de Oliveira Franca, Alexander
R. Precioso, James Logan, Trudie Lang, Nina Jamieson & Eduardo Massad (2019) ZikaPLAN:
addressing the knowledge gaps and working towards a research preparedness network in the
Americas, Global Health Action, 12:1, 1666566, DOI: 10.1080/16549716.2019.1666566
To link to this article:  https://doi.org/10.1080/16549716.2019.1666566
© 2019 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 23 Oct 2019.
Submit your article to this journal 
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=zgha20
Article views: 123
View related articles 
View Crossmark data
CAPACITY BUILDING
ZikaPLAN: addressing the knowledge gaps and working towards a research
preparedness network in the Americas
Annelies Wilder-Smith a, Raman Preeta, Elizabeth B. Brickley b, Ricardo Arraes de Alencar Ximenesc,d,
Demócrito de Barros Miranda-Filho d, Celina Maria Turchi Martellie, Thália Velho Barreto de Araújof,
Ulisses Ramos Montarroyosg, Maria Elisabeth Moreirah, Marília Dalva Turchii, Tom Solomonj, Bart C. Jacobsk,
Carlos Pardo Villamizarl,m, Lyda Osorio m, Ana Maria Bispo de Filipps n, Johan Neyts o,
Suzanne Kaptein o, Ralph Huits p, Kevin K. Ariënp, Hugh J. Willison q, Julia M. Edgarq,
Susan C. Barnett q, Rosanna Peelingb, Debi Boerasb, Maria G. Guzmanr, Aravinda M. de Silvas,
Andrew K. Falconarb,t, Claudia Romero-Vivast, Michael W. Gauntb, Alessandro Setteu,v, Daniela Weiskopfu,
Louis Lambrechts w, Helen Dolk x, Joan K. Morris y, Ieda M. Orioli z, Kathleen M. O’Reilly b,
Laith Yakobb, Joacim Rocklöva, Cristiane Soaresaa, Maria Lúcia Brito Ferreirabb,
Rafael Freitas de Oliveira Francacc, Alexander R. Precioso dd,ee, James Loganb, Trudie Langff,
Nina Jamieson ff and Eduardo Massadgg,hh
aDepartment of Epidemiology and Global Health, Umeå University, Umeå, Sweden; bLondon School of Hygiene & Tropical
Medicine, London, UK; cDepartamento de Medicina Tropical, Universidade Federal de Pernambuco, Recife, Brasil; dDepartamento
de Medicina Interna, Universidade de Pernambuco, Recife, Brasil; eInstituto Aggeu Magalhães, Fundação Oswaldo Cruz, Recife,
Brasil; fDepartamento de Medicina Social, Universidade Federal de Pernambuco, Recife, Brasil; gInstituto de Ciências Biológicas,
Universidade de Pernambuco, Recife, Brasil; hInstituto Fernandes Figueira – Fundação Oswaldo Cruz, Rio de Janeiro, Brasil;
iInstituto de Patologia Tropical e Saúde Publica, Universidade Federal de Goiás, Goiânia, Brasil; jInstitute of Infection and Global
Health, The University of Liverpool, Liverpool, UK; kDepartments of Neurology and Immunology, Erasmus Universitair Medisch
Centrum Rotterdam, The Netherlands; lJohns Hopkins University, Baltimore, MD, USA; mUniversidad del Valle, Colombia;
nLaboratório de Flavivírus, Instituto Oswaldo Cruz, Brazil; oDepartment of Microbiology, Immunology and Transplantation, KU
Leuven, Rega Institute of Medical Research, Leuven, Belgium; pInstitute of Tropical Medicine, Antwerp, Belgium; qInstitute of
Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK; rInsitituto Medicina Tropical, Pedro Kouri, Cuba;
sDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, NC, USA; tDepartmento del Medicina,
Fundacion Universidad del Norte, Barranquilla, Colombia; uDivision of Vaccine Discovery, La Jolla Institute for Allergy and
Immunology, La Jolla, CA, USA; vDepartment of Medicine, University of California San Diego, La Jolla, CA, USA; wInsect-Virus
Interactions Unit, Institut Pasteur, UMR2000, CNRS, Paris, France; xMaternal Fetal and Infant Research Centre, Institute of
Nursing and Health Research, Ulster University, Newtownabbey, UK; yPopulation Health Research Institute, St George’s,
University of London, London, UK; zAssociação Técnico-Científica Estudo Colaborativo Latino Americano de Malformações
Congênitas (ECLAMC) no Departmento de Genética, Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de
Janeiro, Brazil; aaHospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil; bbHospital da Restauração, Recife, Brazil;
ccOswaldo Cruz Foundation, Recife, Brazil; ddInstituto Butantan, Brazil; eePediatrics Department, Medical School of University of
Sao Paulo, Sao Paulo, Brazil; ffThe Global Health Network, Masters and Scholars of the University of Oxford, Oxford, UK;
CONTACT Annelies Wilder-Smith anneliesws@gmail.com Department of Epidemiology and Global Health, Umeå University, 90185 Umeå,
Sweden
ZikaPLAN consortium members and institutions
Annelies Wilder-Smith, Raman Preet, Karl-Erik Renhorn, Joacim Rocklöv, Niklas Arnberg, John Kinsman, David Persson, Stefan Nord, Lena
Mustonen, Sara Forsberg (#1 Umeå University, Sweden); Elizabeth B. Brickley, Laura C. Rodrigues, Ludmila Lobkowicz, Rosanna Peeling, Debi
Boeras, Andrew K. Falconar, Michael Gaunt, Kathleen M O’Reilly, James Logan, Grace Power, Thomas Ant, Laith Yakob, Hannah Kuper, Neal
Alexander (#2 London School of Hygiene & Tropical Medicine, UK); Hugh J. Willison, Julia M. Edgar, Susan C. Barnett (#3 University of Glasgow,
UK); Trudie Lang, Nina Jamieson, Bonny Baker, Liam Boggs (#4 University of Oxford, UK); Joan K Morris (#5 Queen Mary University of London,
UK); Helen Dolk, Leke Aminkeng, Katy Karnell (#6 Ulster University, UK); Johan Neyts, Suzanne Kaptein, Kai Dallmeier (#7 Katholieke Universiteit
Leuven, The Netherlands); Bart C. Jacobs, Sonja E. Leonhard, Melissa Mandarakas (#8Erasmus Universitair Medisch Centrum, The Netherlands);
Louis Lambrechts, Fabian Aubry (#9 Institut Pasteur, France); Claudia Romero-Vivas (#10 Fundacion Universidad del Norte, Colombia); Carlos
Pardo Villamizar, Lyda Osorio (#11 Universidad del Valle, Colombia); Koren Wolman-Tardy, Margaux Lucini, Jason Soffe, Florence Pradel,
Sebasitan Quesney, Richard Vaux (#12 Fondation Mérieux, France); Tom Solomon, Suzannah Lant, Louise Cooper, Mike J Griffiths, Lance Turtle,
Lisa Ng, Ravi Mehta, Raquel Madialdea-Carrera, (#13 University of Liverpool, UK); Alessandro Sette, Daniela Weiskopf (#14 La Jolla Institute for
Allergy and Immunology, USA); Aravinda M. de Silva, Stefan Matz (#15 University of North Carolina at Chapel Hill, USA); Ralph Huits, Kevin
K. Ariën, Liselotte Cnops (#16 Prins Leopald Instituut voor Tropische Geneeskunde, Belgium); Eduardo Massad, Esper Kallas, Amilton A Barreira
(#17 Fundacao de Apoio a Universidade de Sao Paulo, Brazil); Alexander R. Precioso, Ricardo Palacios Gomez, Beatriz da Costa Thome (#18
Instituto Butantan, Brazil); Ieda Orioli, Daniel Mattos (#19 Associação Técnico-Científica Estudo Colaborativo Latino Americano de Malformações
Congênitas (ECLAMC), Brazil); Ana Maria Bispo de Filippis, David Brown, Rafael Freitas de Oliveira Franca, Maria E Moreira, Zilton Vasconselos,
Celina M Turchi, Ernesto TA Marques Jr., Wayner V. de Souza (#20 Fundacao Oswaldo Fiocruz, Brazil); Maria G. Guzman, José Luis Pelegrino,
Mayling Vera Alvarez, Alicia Reyes Jiménez (#21 Instituto Medicina Tropical Pedro Kouri, Cuba); Amadou A Sall, Cheikh Tidiane Diagne (#22
Institut Pasteur de Dakar, Senegal); Christoph Hatz, Andreas Neumayr; Pie Mueller (#23 Schweizerisches Tropen-und Public Health-Institut,
Switzerland); In-Kyu Yoon (#24 International Institute of Vaccine, S Korea); Ricardo A. A. Ximenes, Thália V. Barreto de Araújo, Celina M Turchi
Martelli, Demócrito D. B. Miranda-Filho, Ulisses R. Montarroyos, Marília D. Turchi, Luiza Emylce Pelá Rosado (#25 Universidade Federal de
Pernambuco, Brazil).
GLOBAL HEALTH ACTION
2019, VOL. 12, 1666566
https://doi.org/10.1080/16549716.2019.1666566
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
ggFundacao de Apoio a Universidade de Sao Paulo, Sao Paulo, Brazil; hhSchool of Applied Mathematics, Fundacao Getulio
Vargas, Rio de Janeiro, Brazil
ABSTRACT
Zika Preparedness Latin American Network (ZikaPLAN) is a research consortium funded
by the European Commission to address the research gaps in combating Zika and to
establish a sustainable network with research capacity building in the Americas. Here we
present a report on ZikaPLAN`s mid-term achievements since its initiation in
October 2016 to June 2019, illustrating the research objectives of the 15 work packages
ranging from virology, diagnostics, entomology and vector control, modelling to clinical
cohort studies in pregnant women and neonates, as well as studies on the neurological
complications of Zika infections in adolescents and adults. For example, the
Neuroviruses Emerging in the Americas Study (NEAS) has set up more than 10 clinical
sites in Colombia. Through the Butantan Phase 3 dengue vaccine trial, we have access to
samples of 17,000 subjects in 14 different geographic locations in Brazil. To address the
lack of access to clinical samples for diagnostic evaluation, ZikaPLAN set up a network of
quality sites with access to well-characterized clinical specimens and capacity for inde-
pendent evaluations. The International Committee for Congenital Anomaly Surveillance
Tools was formed with global representation from regional networks conducting birth
defects surveillance. We have collated a comprehensive inventory of resources and tools
for birth defects surveillance, and developed an App for low resource regions facilitating
the coding and description of all major externally visible congenital anomalies including
congenital Zika syndrome. Research Capacity Network (REDe) is a shared and open
resource centre where researchers and health workers can access tools, resources and
support, enabling better and more research in the region. Addressing the gap in
research capacity in LMICs is pivotal in ensuring broad-based systems to be prepared
for the next outbreak. Our shared and open research space through REDe will be used
to maximize the transfer of research into practice by summarizing the research output
and by hosting the tools, resources, guidance and recommendations generated by these
studies. Leveraging on the research from this consortium, we are working towards
a research preparedness network.
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Background
The European Union funded three research consortia to
address the urgent knowledge gaps related to Zika virus
(ZIKV), a newly emerged flavivirus that was declared
a public health emergency of international concern in
2016 due to its unusual complications [1]. The consor-
tium ‘Zika Preparedness Latin American Network’
(ZikaPLAN) combines 25 multinational and interdisci-
plinary institutional partners from Europe, Latin
America, North America, Africa, and Asia. These 25
institutional partners bring together a full range of exper-
tise ranging from entomology, modelling, birth defect
surveillance to clinical studies, coordinated by Umea
University, Sweden. All institutions involved in
ZikaPLAN, the research design, objectives and overall
programme have been described previously in great
detail [2]. Table 1 summarizes the work packages and
the institutions involved per work package, and their
expected impacts. This project was awarded
11.6 million Euro and officially commenced on
1 October 2016, although due to the emergency with
a peak in ZIKV cases in early 2016, some of the groups
started several research projects before the EU funding
arrived. ZikaPLAN is funded for 4 years until
30 September 2020.
ZikaPLAN is a network of networks, far beyond
the 25 beneficiaries as listed in the consortium
description [2]. Some of the networks grew out of
DengueTools [3], further expanded to include part-
ners from the Latin-American region. Through these
networks, we have direct access to various comple-
mentary, fully operational (clinical, laboratory and
surveillance) networks that are being leveraged in
the different studies in ZikaPLAN. These networks
will also function as a springboard to the develop-
ment of the envisaged Latin-American preparedness
and response network in the longer term beyond the
ZikaPLAN funding period. Here we describe only
a selection of such networks, particularly pertinent
to ZikaPLAN:
Brazil`s Microcephaly Epidemic Research Group
(MERG) was quickly established when the outbreak
emerged in North-East Brazil in 2015. It initially
focused on case–control studies, established the link
between ZIKV and microcephaly, and then expanded
its work to set up prospective pregnant women cohort
studies [4–8] (Figure 1). To better investigate birth
defects, ZikaPLAN partners with ECLAMC, the Latin
American Collaborative Study of Congenital
Malformations with 21 active participating hospitals
in 7 countries in South America (www.eclamc.org)
(Figure 2); and EUROCAT, the European surveillance
of congenital anomalies (www.eurocat-network.eu/)
with 43 registries in 23 countries surveying more
than 1.7 million births per year in Europe.
The Neuroviruses Emerging in the Americas
Study (NEAS) is a collaborative network leading
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a multi-center study in the Americas to establish
a comprehensive registry of the clinical, radiological
and laboratory profile of patients with new onset of
neurological disorders associated with Zika virus
infections (www.neasstudy.org) (Figure 3). Given
the links of ZIKV with Guillain-Barre Syndrome
(GBS), the International GBS Outcome Study
(IGOS) is a particularly important network coordi-
nated by ZikaPLAN partner Erasmus University
Medical Center in Rotterdam, The Netherlands [9].
IGOS coordinates clinical data on GBS and bio-
banks, thereby aiming to identify clinical and biolo-
gical determinants and predictors of disease course
in GBS. IGOS also provides a platform to validate
new treatments and to increase the standardization
of care in the participating centers.
A pivotal ZikaPLAN partner is the Global Health
Network (TGHN) based at Oxford University, UK.
TGHN is a knowledge-sharing hub that provides
capacity building and process improvement through
online platforms, regional and online training,
resources and professional development to build
skills and careers that deliver evidence to change
practice.
Another institutional partner is Butantan.
Instituto Butantan is a Brazilian biologic research
center located in São Paulo, Brazil. Instituto
Butantan is a public institution affiliated with the
São Paulo State Secretariat of Health and consid-
ered one of the major scientific centers in the
world. Butantan is currently running the large
Phase 3 trial for a tetravalent live-attenuated den-
gue vaccine [10] with about 17,000 subjects aged 2
to 59 in 14 locations throughout Brazil. Blood
samples will be taken from all trial participants,
and Butantan kindly agreed for ZikaPLAN to do
a ZIKV seroprevalence study based on a randomly
selected sample from those 17,000 subjects
(Figure 1).
In addition to the above, to maximize the scien-
tific output and networks, ZikaPLAN collaborates
closely with the two other EU-funded consortia
called ZIKAlliance (https://zikalliance.tghn.org) and
ZIKAction (zikaction.org/).
ZikaPLAN`s 15 work packages were designed to
[1] address the urgent knowledge gaps to effectively
address the problems of ZIKV and [2] build up
a research preparedness network in Latin America
and the Caribbean region (Table 1). All publications
as a result of ZikaPLAN to date can be found at
https://zikaplan.tghn.org/.
For the sake of accountability, transparency and
timely dissemination, here we provide a report on
ZikaPLAN`s mid-term achievements to June 2019,
both in terms of addressing the knowledge gaps and
initial steps taken to set up a research preparedness
network.Ta
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(I) Addressing research gaps
Investigating congenital Zika syndrome
Following the emergence of microcephaly in Northeast
Brazil in 2015 [11], the causal link between maternal
ZIKV infection and birth defects was rapidly con-
firmed by other groups and by ZikaPLAN`s
Microcephaly Epidemic Research Group (MERG)
[5,12]. Nevertheless, the absolute risks of miscarriage,
stillbirth, microcephaly, and other manifestations of
Congenital Zika Syndrome (CZS) in pregnancies with
ZIKV infections remained unknown. To address this
gap in knowledge, our team of ZikaPLAN-affiliated
investigators worked in coordination with the
Brazilian Ministry of Health’s ZIKV surveillance pro-
grams to initiate prospective cohort studies of preg-
nant women residing in three of the five regions of
Brazil: Recife in the Northeast, Goiânia in the Central-
west, and Rio de Janeiro in the Southeast. For the
cohort studies, we began recruiting pregnant women
with rash mid-epidemic in 2015 and closed enrollment
with the decline in transmission in 2017, given the
rapid global decline in cases. We tested all pregnant
women for ZIKV infections using robust laboratory
assays, such as quantitative reverse transcription poly-
merase-chain reaction (qRT-PCR), Immunoglobulin
(Ig) M and IgG3 enzyme-linked immunosorbent
assays (ELISAs), and Plaque Reduction Neutralization
Tests (PRNT50). Our clinical teams prospectively mon-
itored the pregnancies for a range of adverse fetal and
birth outcomes.
Analyses based on the pregnancy cohort data are
underway to determine the spectrum of risks asso-
ciated with ZIKV infections in pregnancy and to com-
pare the attack rate of CZS by gestational week of
infection and region. In addition to conducting
detailed epidemiological analyses within each of the
three ZikaPLAN study sites, our team of investigators
is also leveraging our data in order to contribute to
a series of individual participant data meta-analyses
Figure 1. Microcephaly Epidemic Research Group (MERG), Neuro-Zika, and the clinical sites of the Butantan Phase 3 trial for
dengue vaccine.
RENAC – Argenna
RENACH - Chile
RRMC -Maule, Chile
SINASC - Brazil
SINASC MSP-Município São
Paulo, BrazilPNPDC – Paraguay
RNDCER- Uruguay
CBDSP – Cali, Colombia
PVSDCB – Bogota, Colombia
SIVIGILA - Colombia
PNMC – Panama
CREC – Costa Rica
RECUMAC – Cuba
SVDC – Nicaragua
ReDeCon HU - Nuevo Leon, Mexico
RYVEMCE -Mexico
Figure 2. Birth defect surveillance network (RELAMC).
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(IPD-MAs). These IPD-MAs include: (i) the
Consórcio Coortes Brasil, which is informing ZIKV
epidemic preparedness policies in Brazil, (ii) the
pooled analysis of results from the EU-funded Zika
Consortia, which is facilitating the sharing of best
practices and epidemiological methods across the
research consortia, and (iii) the WHO-led ZIKV IPD
Consortium, which is enabling global pooling of data
across all eligible studies [13]. By pooling participant-
level data across studies, these IPD-MAs will increase
the statistical power for assessing the risks associated
with ZIKV infection within potentially important clin-
ical subgroups, such as dengue co-infected pregnant
women. Further, by including a diversity of popula-
tions, these collaborative data-sharing efforts will allow
for meaningful investigations into the sources of het-
erogeneity in the current estimates of absolute and
relative risks of adverse outcomes associated with con-
genital ZIKV infections. The protocol for the IPD-MA
of longitudinal studies of pregnant women and their
infants and children has meanwhile been pub-
lished [13].
Because the ZikaPLAN-affiliated study sites repre-
sent some of the first research teams to investigate
microcephaly, we are privileged to be able to follow
some of the world`s largest cohorts of children with
CZS. This valuable work has been supported by the
EU funding for ZikaPLAN as well as the Wellcome
Trust, the UK Department for International
Development, the Medical Research Council, the
Brazilian Conselho Nacional de Desenvolvimento
Cientifico e Tecnológico, the Secetaria de Vigilancia
de Saude, the Fundação do Amparo a Ciência
e Tecnologia, and other sources. For this research,
children have been recruited from our team’s case–
control study [4,14], the prospective pregnancy
cohorts, and by clinical referral. In total, our multi-
disciplinary teams are prospectively following more
than 500 children with prenatal ZIKV exposure,
approximately half of whom have microcephaly, as
well as children who were ZIKV-unexposed. During
follow-up visits, a ‘task force’ of clinical specialists,
including pediatricians, neurologists, otolaryngologists,
speech pathologists, ophthalmologists, infectious dis-
ease physicians, dieticians, and physical therapists eval-
uate the wellbeing of the children and carefully
monitor for any physical developmental abnormalities.
Children’s neurodevelopment is assessed using the
Survey of Well-being in Young Children [15], the
General Movement Assessment tool [16], and the
Bayley Scales of Infant and Toddler Development,
third edition (Bayley-III) [17]. Findings from 94 chil-
dren without microcephaly who underwent both neu-
roimaging and Bayley-III testing as part of the Rio de
Janeiro-based cohort indicate that the odds of having
a Bayley-III score 2 SD below the mean is significantly
higher among children with abnormal versus normal
brain imaging [18]. Among children with ZIKV-
related microcephaly, we have observed functional
impairments related to feeding behaviors and
a worsening of their nutritional status during the cri-
tical first 1000 days of development [19]. Further, our
Hospital UniversitarioErasoMeoz
Cúcuta, Norte de Santander
ClínicaLa Misericordia
Barranquilla, Atlántico
ClínicaLeón XIII
Medellín, Antioquia
Centro MédicoImbanaco, Clínica
Rey David, FundaciónClínicaValle 
de Lili, FundaciónClub Noel, 
Hospital Universitariodel Valle, 
Hospital San Juan de Dios 
Cali, Valle del Cauca
Hospital Universitariode Neiva
ClínicaMedilaser
Neiva, Huila
Hospital Departamentalde Nariño
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Figure 3. Neuro Emerging Viruses in the Americas Study (NEAS).
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research indicates that, even in the absence of micro-
cephaly, a subset of infants with prenatal ZIKV expo-
sure exhibit impaired motor function with a lower
number of age-specific movement patterns than their
neurotypical, unexposed peers [20]. Additional ana-
lyses are ongoing to describe the full range of CZS-
related abnormalities and its evolution in the early life
course and across our diverse study settings. The full
list of publications associated with the ZikaPLAN
cohort studies from the beginning of the ZIKV out-
break until June 2019 is summarized in Table 2.
Support for affected communities, in particular,
access to health care for children with CZS and
their families is a priority, and to this end,
ZikaPLAN partners are working towards family sup-
port programmes [21,22].
Table 2. Scientific publications by the Microcephaly Epidemic Research Group (MERG) in North-East Brazil and ZikaPLAN Work
Package 1 Partners, from 2015 to present.
1. Castanha, P. M. S. et al. Perinatal analyses of Zika- and dengue virus-specific neutralizing antibodies: A microcephaly case-control study in an area
of high dengue endemicity in Brazil. PLoS Neglected Tropical Diseases, 13:1–17, 2019.
2. Souza, W. V. et al. Microcephaly epidemic related to the Zika virus and living conditions in Recife, Northeast Brazil. BMC Public Health, 18:130–136,
2018.
3. Araujo, T. V. B. et al. Association between microcephaly, Zika virus infection, and other risk factors in Brazil: final report of a case-control study.
Lancet Infectious Diseases, 18:328–336, 2018.
4. Albuquerque, M. F. P. M. et al. The microcephaly epidemic and Zika virus: building knowledge in epidemiology. Cadernos de Saúde Pública, 34:
1–13, 2018.
5. Pires, P. et al. Neuroimaging findings associated with congenital Zika virus syndrome: case series at the time of first epidemic outbreak in
Pernambuco State, Brazil. Childs Nervous System, 34:957–963, 2018.
6. Miranda-Filho, D. B. et al. Initial Description of the Presumed Congenital Zika Syndrome. American Journal of Public Health, 106:598–600, 2016.
7. Albuquerque, M. F. P. M. et al. Microcephaly in Infants, Pernambuco State, Brazil, 2015. Emerging Infectious Diseases, 22:1090–1093, 2016.
8. Araujo, T. V. B. et al. Association between Zika virus infection and microcephaly in Brazil, January to May, 2016: preliminary report of a case-control
study. Lancet Infectious Diseases, 16:1356–1363, 2016.
9. Albuquerque, M. F. P. M. et al. Pyriproxyfen and the microcephaly epidemic in Brazil – an ecological approach to explore the hypothesis of their
association. Memórias do Instituto Oswaldo Cruz, 111:774–776, 2016.
10. Souza, W. V. et al. Microcephaly in Pernambuco State, Brazil: epidemiological characteristics and evaluation of the diagnostic accuracy of cutoff
points for reporting suspected cases. Cadernos de Saude Publica, 32(4):e00017216, 2016.
11. Leal, M. C. et al. Hearing Loss in Infants with Microcephaly and Evidence of Congenital Zika Virus Infection – Brazil, November 2015–May 2016.
Morbidity and Mortality Weekly Report, 65(34):917–919, 2016.
12. Franca, R. F. O. et al. First International Workshop on Zika Virus Held by Oswaldo Cruz Foundation (Fiocruz) in Northeast Brazil March 2016 –
A Meeting Report. PLOS Neglected Tropical Diseases, 10(6):e0004760, 2016.
13. Cordeiro, M. T. et al. Results of a Zika Virus (ZIKV) Immunoglobulin M–specific diagnostic assay are highly correlated with detection of neutralizing
anti-ZIKV antibodies in neonates with congenital disease. The Journal of Infectious Diseases, 214:1897–1904, 2016.
14. Poretti, A. et al. Zika virus infection during pregnancy and small heads: What is the connection and what can be seen by imaging. Atlas of Science.
2016. Avaliable in: <http://atlasofscience.org/zika-virus-infection-during-pregnancy-and-small-heads-what-is-the-connection-and-what-can-be-
seen-by-imaging/>
15. Hazin, A. N. et al. Computed tomographic findings in microcephaly associated with Zika Virus. The New England Journal of Medicine,
374(22):2193–2195, 2016.
16. Einspieler C, Utsch F, Brasil P, Panvequio Aizawa CY, Peyton C, Hydee Hasue R, et al. Association of Infants Exposed to Prenatal Zika Virus Infection
With Their Clinical, Neurologic, and Developmental Status Evaluated via the General Movement Assessment Tool. JAMA Netw Open. 2019;2(1):
e187235. Epub 2019/01/19. doi: 10.1001/jamanetworkopen.2018.7235. PubMed PMID: 30657537; PubMed Central PMCID: PMCPMC6431234.
17. Brickley EB, Rodrigues LC. Further pieces of evidence in the Zika virus and microcephaly puzzle. Lancet Child Adolesc Health. 2018;2(3):162–4.
Epub 2018/09/01. doi: 10.1016/S2352-4642(18)30021-X. PubMed PMID: 30169250.
18. Lopes Moreira ME, Nielsen-Saines K, Brasil P, Kerin T, Damasceno L, Pone M, et al. Neurodevelopment in Infants Exposed to Zika Virus In Utero.
N Engl J Med. 2018;379(24):2377–9. Epub 2018/12/24. doi: 10.1056/NEJMc1800098. PubMed PMID: 30575464.
19. Devakumar D, Bamford A, Ferreira MU, Broad J, Rosch RE, Groce N, et al. Infectious causes of microcephaly: epidemiology, pathogenesis, diagnosis,
and management. Lancet Infect Dis. 2018;18(1):e1-e13. Epub 2017/08/29. doi: 10.1016/S1473-3099(17)30398-5. PubMed PMID: 28844634.
20. Lowe R, Barcellos C, Brasil P, Cruz OG, Honorio NA, Kuper H, et al. The Zika Virus Epidemic in Brazil: From Discovery to Future Implications.
Int J Environ Res Public Health. 2018;15(1). Epub 2018/01/10. doi: 10.3390/ijerph15010096. PubMed PMID: 29315224; PubMed Central PMCID:
PMCPMC5800195.
21. Paixao ES, Teixeira MG, Costa M, Barreto ML, Rodrigues LC. Symptomatic Dengue during Pregnancy and Congenital Neurologic Malformations.
Emerg Infect Dis. 2018;24(9):1748–50. Epub 2018/08/21. doi: 10.3201/eid2409.170361. PubMed PMID: 30124410; PubMed Central PMCID:
PMCPMC6106414.
22. Paixao ES, Leong WY, Rodrigues LC, Wilder-Smith A. Asymptomatic Prenatal Zika Virus Infection and Congenital Zika Syndrome. Open Forum
Infect Dis. 2018;5(4):ofy073. Epub 2018/05/08. doi: 10.1093/ofid/ofy073. PubMed PMID: 29732381; PubMed Central PMCID: PMCPMC5925427.
23. Paixao ES, Teixeira MG, Rodrigues LC. Zika, chikungunya and dengue: the causes and threats of new and re-emerging arboviral diseases. BMJ Glob
Health. 2018;3(Suppl 1):e000530. Epub 2018/02/13. doi: 10.1136/bmjgh-2017-000530. PubMed PMID: 29435366; PubMed Central PMCID:
PMCPMC5759716.
24. Paixao ES, Costa M, Teixeira MG, Harron K, de Almeida MF, Barreto ML, et al. Symptomatic dengue infection during pregnancy and the risk of
stillbirth in Brazil, 2006–12: a matched case-control study. Lancet Infect Dis. 2017;17(9):957–64. Epub 2017/08/29. doi: 10.1016/S1473-3099(17)
30366-3. PubMed PMID: 28845800; PubMed Central PMCID: PMCPMC6205624.
25. Rodrigues LC, Paixao ES. Risk of Zika-related microcephaly: stable or variable? Lancet. 2017;390(10097):824–6. Epub 2017/06/26. doi: 10.1016/
S0140-6736(17)31478-2. PubMed PMID: 28647174.
26. Rodrigues LC. Zika’s Long Haul: Tackling the Causes of Human Vulnerability to Mosquito-Borne Viruses. Am J Public Health. 2017;107(6):831–3.
Epub 2017/05/13. doi: 10.2105/AJPH.2017.303792. PubMed PMID: 28498761.
27. Wilder-Smith A, Wei Y, Araújo TVB, VanKerkhove M, Turchi Martelli CM, Turchi MD, et al. Understanding the relation between Zika virus infection
during pregnancy and adverse fetal, infant and child outcomes: a protocol for a systematic review and individual participant data meta-analysis of
longitudinal studies of pregnant women and their infants and children. BMJ Open. 18 June 2019;9(6):e026092. doi: 10.1136/bmjopen-2018-
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28. Moreira MCN, Nascimento M, Mendes CHF, Pinto M, Valongueiro S, Moreira MEL, Lyra TM, Kuper H; SEIZ Research Group. Emergency and
permanence of the Zika virus epidemic: an agenda connecting research and policy. Cad Saude Publica. 2018;34(8):e00075718.
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The Zika epidemic in Latin America has brought
the world’s attention to the need for effective con-
genital anomaly (birth defect) surveillance systems.
The Birth Defect Surveillance Group within
ZikaPLAN is investigating the epidemiology of CZS
and is aiming to strengthen birth defects surveillance
in Latin America and other low resource regions of
the world. We formed the International Committee
for Congenital Anomaly Surveillance Tools with glo-
bal representation from regional networks conduct-
ing birth defects surveillance. This committee has
collated a comprehensive inventory of resources and
tools for birth defects surveillance available on the
newly launched global birth defects website (https://
globalbirthdefects.tghn.org). An App for low resource
regions facilitating the coding and description of all
major externally visible congenital anomalies includ-
ing microcephaly and CZS will begin field-testing in
March 2019. Furthermore, we launched the Red
Latino Americana de Malformaciones Congénitas
(RELAMC), a network of population-based congeni-
tal anomaly registries, in November 2018. Data from
RELAMC on microcephaly in the pre-ZIKV period
have been analysed to provide a baseline [23]. PAHO
and RELAMC registry data on microcephaly and CZS
as well as any information on congenital maternal
infection syndromes in Latin America are currently
being analysed.
Studying the neurological complications of Zika
The full spectrum of neurological disease associated
with ZIKV, beyond congenital disease, is poorly
understood, and case definitions are further compli-
cated by the fact that other arboviruses such as den-
gue and chikungunya viruses often co-circulate
causing similar disease. The frequency of these neu-
rological manifestations is unknown, although, for
Guillain-Barré syndrome (GBS) after Zika, it is esti-
mated to be 2.0 [95% credible interval 0.5–4.5] per
10,000 cases of Zika infection [24]. To address this,
we established a Zika Neurology Network (ZNN) in
Brazil and retrospectively studied neurological disease
cases associated with ZIKV in Rio de Janeiro from
November 2015 to June 2016. We found that ZIKV
was associated with a wide range of central and
peripheral nervous system manifestations, including
meningoencephalitis, myelitis, acute disseminated
encephalomyelitis, radiculitis and GBS; chikungunya
virus appeared to have an equally important associa-
tion with neurological disease in Brazil, and many
patients had dual infection [25]. To investigate this
further, we set up parallel case–control studies in
Brazil through the ZNN and in Colombia with the
NEAS network, recruiting patients presenting with
new onset of a neurological syndrome of unknown
etiology, including but not limited to encephalitis,
meningitis, myelitis, GBS and cranial nerve disease,
plus controls. By June 2019, 137 cases with GBS, 245
cases of CNS or cranial nerve inflammatory disorders
and 715 controls have been recruited in Brazil, whilst
126 patients with GBS, 64 with CNS inflammatory
disorders, and 93 controls have been recruited in
Colombia. Analyses are underway, and we expect
that the relative proportion of ZIKV as a cause for
neurological disease has declined over time; never-
theless, understanding the role of other arboviral dis-
eases in the pathomechanism of neurological disease
is equally important so that we continue to build up
this project despite the disappearance of ZIKV as
a public health problem.
The unusual clusters of ZIKV associated GBS were
first described by other groups in French Polynesia
[26]. We expanded the already existing IGOS, the
largest global observational cohort study on GBS
[9], to establish a case–control study for Zika (IGOS-
Zika), that is now running in nine hospitals across
three countries (Brazil, Argentina, Malaysia).
International data and sample collection were further
standardized by sharing the IGOS protocol with net-
works in Latin America (NEAS, CDC, Zika
Neurology Network) [27]. The IGOS database will
also facilitate the comparison between ZIKV-related
GBS and GBS after other infections. Additionally,
collaborations with local neurologists in Recife,
Brazil, are ongoing to describe a GBS cohort collected
early in the ZIKV outbreak. As clinical guidelines for
the management of GBS are currently lacking [28],
we developed a globally applicable consensus report
in collaboration with international and local experts
to support the diagnosis and management of GBS.
This guideline, as well as results from an ongoing
survey amongst Brazilian neurologists, will be used
to develop training material and courses in collabora-
tion with The Global Health Network.
It is important to discover and characterise the
mechanistic pathways of ZIKV infection in the patho-
genesis of central (CNS) and peripheral nervous sys-
tem (PNS) injury, focusing on both direct viral
invasion, and the immune and autoimmune
responses to viral infection. ZIKV tropism in the
peripheral and central nervous systems (PNS and
CNS, respectively) has now been defined in vitro
and these data are guiding progress through in vivo
work in which a neurological phenotype is also seen.
We found the resistance of Schwann cells to infec-
tion, compared with CNS cells [29]. Different viral
isolates show different tropisms for nervous system
cells. We are using infection of induced pluripotent
neural stem cells and other neural cells to conduct
drug screens. Identification of ZIKV main cellular
receptors on human neural cells is ongoing with
unbiased and candidate approaches. Studies using
sera from Zika-GBS cases and controls have been
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screened for known GBS antigen targets, but to date,
no antigen targets have been found indicating the
ZIKV associated GBS may have a unique autoim-
mune signature. We have now expanded this work
to include different in vitro culture systems. The
cellular studies to examine differential immune
responses in patients with non-neurological ZIKV
infection, patients with viral invasion of the CNS
(e.g. encephalitis) and patients with autoimmune
neurological disease are awaiting the collection of
carefully archived clinical samples obtained from
ZikaPLAN`s studies in various hospitals in Brazil
and Colombia.
Developing diagnostics for Zika
Lack of suitable diagnostic assays has hampered Zika
research and the public health emergency response
[30]. Novel diagnostics often do not make it to the
finish line due to lack of access to specimens needed
and need to be validated before use in a clinical
setting [31]. To address these barriers, ZikaPLAN
set up a network to accelerate the development and
evaluation of Zika diagnostics for clinical and surveil-
lance use. To this end, a network of quality sites with
access to well-characterized clinical specimens and
capacity for independent evaluations were selected
based on GCP/GCLP criteria. Specimens from con-
firmed Zika positive and negative patients as well as
from dengue confirmed patients are being collected
during the acute and convalescent stage. Sites adhere
to the same protocol standards and compare new
diagnostics to reference standards. A network of
sites provides the framework for a global biobank
and quality laboratories for multi-site evaluations
with rapid data collection, analysis and reporting.
Standardized panels are representative of different
geographic areas. Two of these commercial assays
have been evaluated at three study sites in
Colombia, Senegal and Thailand, and which were
designed to detect patients’ specific anti-ZIKV IgG
and IgM antibodies. Additional four or more assays
will be evaluated in 2019. While the results are still
pending, this approach reduced the time for test
evaluations and hence can resolve the bottleneck for
market entry of ZIKV diagnostics.
To enhance diagnostics development, ZikaPLAN
has been actively involved in characterizing
humoral and T cell responses. Through compari-
sons of known epitope sequences in their native
structural conformations on target proteins from
other flaviviruses with the corresponding sequences
of ZIKV, candidate-conserved and cross-reactive
ZIKV B-cell epitopes were identified on the E and
NS1 proteins, while these ZIKV T cell epitopes
were identified in the NS3 and NS5 protein
sequences [32]. Patients who encountered
sequential DENV and ZIKV infections generated
much stronger CD4+ and CD8 + T-cell responses
during the subsequent ZIKV infection due to the
presence of common epitopes on these viruses,
despite the major target proteins for T cell
responses on ZIKV being different from those on
the DENVs [33]. The ontogeny of the B-cell and
T-cell responses of a ZIKV infected, but DENV-
naïve, patient were also fully assessed [34]. In
a more recent study, we showed that CD8 +
T-cells generated against ZIKV to exhibit an upre-
gulated immune activation, cytokine production
and target cell cytotoxicity gene profiles [35].
ZikaPLAN researchers also analysed the molecular
specificity of the human antibody response to ZIKV.
Using human monoclonal antibodies isolated from
Zika patients, type-specific epitopes on domains I, II
and III of the ZIKV envelope (E) protein were
defined [36]. Recombinant antigens displaying type-
specific epitopes were useful for the sero-diagnosis of
ZIKV infections [37]. These antigens have been used
to understand the sero-epidemiology of ZIKV in Asia
and Latin America [38]. New diagnostic antigens
have been shared with collaborators in academia
and industry to support the development of rapid
diagnostic tests.
To date, we have prepared various chimeric con-
structs encoding the pre-membrane (prM) encoding
genes of either the African or French Polynesian/
South American strains with those encoding the
main envelope (E) for expression as recombinant
viral-like particles in mammalian and insect cells.
Importantly, these constructs will be used in func-
tional (cell-binding and antibody-dependent
enhancement (ADE) assays to account for the ZIKV
strain variations observed from previous sequence
analysis) [39].
The antigenic sites implicated in the generation
of a dramatic and lethal dengue virus ADE in
outbred mice using polyclonal and monoclonal
antibodies [40] are now also being tested against
ZIKV. Recombinant subunit antigens and synthetic
peptide preparations, based on their protein x-ray
diffraction structural determinations or computer
predictions, are also being prepared to assess their
diagnostic, ADE and pathogenic capacities. The
first of our studies on ZIKV CD8 + T-cell epitope
analysis together with their gene expression profiles
were performed and published and they also
showed these ZIKV responses were robust and
not affected by geographical location, time after
ZIKV infection or previous DENV infections [35].
Chimeric constructions of different (e.g. African,
Asia/Pacific and American) ZIKV strains have
been prepared by our team as virus-like particles
(VLPs) to confirm their roles in pathogenesis by
target cell-binding and ADE.
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Exploring reasons for the explosive emergence of
ZIKV
The factors that have fueled the explosiveness and
magnitude of ZIKV emergence in the Pacific and
the Americas are still poorly understood.
Reciprocally, the lack of major human epidemics of
ZIKV in regions with seemingly favorable conditions,
such as Africa or Asia, remains largely unexplained
[41]. The potential contribution of vector population
diversity to ZIKV epidemiological patterns may have
been overlooked. To address this question, we estab-
lished dose–response curves for eight field-derived
populations of the major vector Aedes aegypti repre-
senting the global range of the species, following
experimental exposure to six low-passage ZIKV
strains spanning the current viral genetic diversity.
Our results revealed that African Ae. aegypti are sig-
nificantly less competent than non-African Ae.
aegypti across all viral strains tested. This finding
suggests that low vector competence may have con-
tributed to preventing large-scale human transmis-
sion of Zika virus in Africa (manuscript in
preparation).
Tracing the phylogenetic history and spatio-
temporal dispersal pattern of ZIKV in Asia prior to
its explosive emergence in the Pacific and the
Americas, there was an extended period of relatively
silent transmission in South-East Asia, enabling the
virus to expand geographically and evolve adaptively
before its unanticipated introduction to immunologi-
cally naive populations on the Pacific islands and in
the Americas, as reported by other groups [41].
Substitutions in ZIKV may be implicated in strain
variation in the emergence of ZIKV strains from
Africa into South and South-east Asia [41]. The
amino acid substitutions, possibly implicated in the
neurological pathogenesis and possible antibody-
dependent enhancement (ADE) of severe ZIKV
strains that emerged in French Polynesia and subse-
quently swept through Latin America, were also iden-
tified [39].
To explore whether there is a differential viral
fitness between contemporary ZIKV strains versus
historic ZIKV strains, we are in the process of study-
ing histopathological changes as well as viral load in
brain, spinal cord and testicles in mice. Various
mouse species were first evaluated for their suscept-
ibility to ZIKV infection. Both immunocompromised
(AG129 and Ifnar−/-) and immunocompetent
(C57BL/6 and BALB/c) mice were inoculated with
the ZIKV MR766 prototype strain, obtained from
the European Virus Archive (EVA) (http://www.eur
opean-virus-archive.com). Since immunocompetent
mice are generally resistant to infection with flavi-
viruses, immunocompetent mice were treated with an
interferon (IFN) receptor-blocking antibody prior to
infection to render them more susceptible to ZIKV
replication. In contrast, both AG129 mice and
Ifnar−/- mice are highly susceptible to flavivirus infec-
tions because these mice lack receptors for IFN-α/β
(Ifnar−/-) as well as IFN-γ (INF-α/β/γR-/-/-: AG129).
We showed that ZIKV replicated well in all mice
except in C57BL/6, where half of the mice were non-
responsive to ZIKV infection. Next, virus-induced
disease brought about by a historical and
a contemporary ZIKV strain, the MR766 strain
from EVA and the SL1602 isolate from Suriname
[42], respectively, was evaluated only in AG129
mice. Inoculation with the SL1602 strain resulted in
a faster progression to disease than was the case with
MR766 (manuscript in preparation). Altogether,
these studies demonstrate that AG129 mice are sui-
table to study the viral fitness of contemporary versus
historic ZIKV strains.
In humans, several other research groups have
shown that ZIKV RNA and infectious virus have
been detected in semen up to 6 months and 3 months
post infection, respectively [43]. In the initial phase of
the epidemic, there were concerns that sexual trans-
mission may increase the risk of infection and epi-
demic size. These concerns have been abated using
mathematical modeling by our group [44], which
illustrated that for sexual transmission to be a stand-
alone epidemic threat, the duration of infectiousness
would need to be beyond biologically plausible
values.
Investigating the evolution of the Zika epidemic
Analyses of viral genomes with ecological and epide-
miological data yield an estimate that ZIKV was pre-
sent in Northeast Brazil by February 2014 and is
likely to have disseminated from there, nationally
and internationally, before the first detection of
ZIKV in the Americas [45]. This was corroborated
by a ZikaPLAN`s modeling study [46]. Collating
information on confirmed and suspected Zika cases
across Latin-American countries [https://github.com/
kath-o-reilly/Zika-LAC-Outbreaks] a spatio-temporal
dynamic transmission model for ZIKV infection was
used to project its incidence in 90 major cities within
35 countries. A key output from the model included
the clear demonstration that the ZIKV epidemic pre-
dominantly finished before 2018, with potential for
only small pockets of low numbers of infections
occurring in the region since [47]. Fitting to, and
validation with, region-wide incidence data from the
complete epidemic has resulted in unparalleled
robustness in model parameterisation, allowing for
new insights into the spatial evolution of the epi-
demic. Unusually, flight data seemed to provide
a poor fit to the region-wide spread of infection.
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Instead, Zika’s spread was best explained by a model
of infection that followed land travel to nearby large
cities [47]. Our modelling findings confirm that the
ZIKV epidemic is by and large over within Latin
America. Local low levels of transmission are prob-
able, but the estimated rate of infection suggests that
most cities in Latin America have a population with
high levels of herd immunity. Of note, ZIKV con-
tinues to circulate at a low level in Asia [48] and
Africa, with small clusters of outbreaks in India and
Angola [49,50].
Predictions on further ZIKV epidemiology also
have implications on the use of potential ZIKV vac-
cines. WHO has developed a target product profile
for a ZIKV vaccine for outbreak use. ZikaPLAN pre-
sents a model to optimize a vaccination campaign
aiming to prevent or to curb a Zika virus outbreak.
We show that the optimum vaccination strategy to
reduce the number of cases by a mass vaccination
campaign should start when infected Aedes mosqui-
toes reach a density of greater than 1.5 mosquitoes
per humans [51].
Lastly, thanks to the access to Butantan`s blood
samples in the context of a Phase 3 dengue vaccine
trial among 17,000 subjects in Brazil, we are currently
also in the process of conducting a seroprevalence
study for Zika, stratified by age, gender, geographic
location and prior dengue exposure to better under-
stand the evolution of Zika in Brazil.
Exploring the role of travel and travellers
The explosive spread of Zika virus in theWestern hemi-
sphere has been attributed to the ever-increasing
volume of international travellers to countries with
vector-borne transmission [52]. Consequently, many
travellers were affected during the outbreak [53–59],
and travellers served as sentinel to unmask Zika trans-
mission in countries beyond the Americas
[53,56,59,60]. Graded evidence for best practices
[61,62] will be needed for travellers, and sentinel sur-
veillance in returning travellers is one important tool to
study the burden, evolution over time and spectrum of
disease in travellers. ZikaPLAN is working with two
networks that offer sentinel surveillance. GeoSentinel
is the largest sentinel network in returning travellers
[63], which allows to investigate the effect of purpose or
sub-population of travel [64,65], destination [66,67], as
well as disease-specific questions [68–70]. Through
GeoSentinel, we are currently exploring the geographic
spread of Zika in travellers globally over time.
Furthermore, expanding from our previous collabora-
tion with the European network on sentinel surveillance
in returning travellers (TropNet) through DengueTools
[71], we prospectively enrolled travellers with labora-
tory-confirmed ZIKV infections. We found the inci-
dence rate of ZIKV infection in European travellers to
affected territories to be as high as 17% (95% confidence
interval, 8 to 32) per month of travel during the height
of the outbreak [72]. In this study, all symptomatic
travellers had been infected within 3 weeks of arrival
in areas that reported ZIKV circulation. Asymptomatic
ZIKV infection was rare in this population without
prior exposure to flavivirus infections. We calculated
that ZIKV-infection can be safely ruled out when nega-
tive results are obtained in an NS1-based ZIKV-
antibody detection assay, performed at 20–24 days
post symptom onset or last possible exposure [73].
Virus shedding in the semen is close to zero for dengue
[74,75] but in line with studies from endemic areas [43],
ZikaPLAN found that 60% of male ZIKV cases among
returning travellers had detectable ZIKV RNA in their
semen for a median duration of 83 days [76]. These
findings led to the pre-conception guidance for travel-
lers [77]. With the rapid global decline of ZIKV infec-
tions, we discontinued the studies in travellers in 2017,
and are now focusing on mosquito trap studies distrib-
uted via international travellers.
Furthermore, ZikaPLAN is working with BlueDot
which has access to air passenger data through
International Air Transport Association (IATA) on
various modelling exercises to determine the spread
of Zika and other viruses via transportation networks
in particular via air travel [46,49,78–80].
Addressing best practices for vector control
By transmitting dengue, chikungunya and yellow fever
viruses as well as ZIKV, Aedes (Ae.) aegypti mosquitoes
exert a huge toll on global health. This mosquito species
is highly invasive, continually expanding its global dis-
tribution each year [81]. Despite significant investments,
the incidence of arboviral infections continues to show
a steady upward trend. Novel arbovirus vector control
tools are desperately needed and several alternative
approaches are currently under development with pre-
liminary trials underway to meet this need [82]. Two
novel approaches that have shown considerable promise
in field trials in recent years are the development of
mosquitoes that are resistant to arboviral infection and
the genetic control of Ae. aegypti mosquitoes.
Transinfection of mosquitoes with Wolbachia,
a naturally occurring endosymbiotic bacterium, reduces
mosquito infection with all of these arboviruses [83].
Genetic control using a technology known as RIDL (the
Release of Insects carrying Dominant Lethal genes)
gives rise to non-viable offspring thereby suppressing
the mosquito populations [83,84]. ZikaPLAN`s model-
ling research has highlighted that these technologies
used together can give rise to phenomenal synergisms,
facilitating both the suppression of the wild mosquito
vectors and the spread of their arbovirus-resistant
(Wolbachia-carrying) replacements. Simulations using
a mathematical model, parameterized with new
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Brazilian data, were conducted to compare and contrast
projections of vector control achieved with the alterna-
tive approaches. Used as a standalone approach, both
technologies have their disadvantages: RIDL suppres-
sion of the mosquito population is temporary and
Wolbachia deployments may produce transient
increases in resident mosquito populations. However,
strategically combining both approaches resulted in
mitigation of the risks of inadvertent exacerbation of
the wild mosquito population and longer term con-
trol [85].
Improving personal protection against Aedes
mosquitoes
Although a number of promising arbovirus transmis-
sion-blocking/population-suppression technologies
are currently in development for Aedes mosquitoes,
such as Wolbachia [86] and sterile-male releases [87],
there are a deficit of immediately implementable
solutions. Personal protective technologies (PPT),
such as repellent clothing, exist and show efficacy
[88], but are seldom utilised on a large scale [89,90].
We conducted focus group interviews involving preg-
nant women in Colombia with the aim of identifying
areas where PPT product design and information
dissemination can be refined to encourage uptake.
Using our findings, we are developing durable repel-
lent formulations utilising cyclodextrin technologies
that can be conveniently applied to clothing at home.
(II) Research preparedness networks, capacity
building, dissemination, and sustainability
We have developed a platform called REDe (www.
REDe.tghn.org) through the Global Health Network
based at Oxford University (www.TGHN.org). This is
a research capacity network and knowledge exchange
platform that is a shared output from the three EU
funded Zika consortia (ZikaPLAN, ZIKAction and
ZIKAlliance). The aim is to create a strong network
between all organisations and groups working on
ZIKV and to use this as a mechanism to be ‘research
ready’ for the next outbreak, as well as for disseminating
outputs and recommendations from these studies in
a highly accessible facility. Addressing the gap in
research capacity in LMICs is pivotal in ensuring broad-
based systems improvement, with local knowledge and
training being central to responsive health system
development [91]. Local solutions are also more likely
to have buy-in from local providers and policymakers,
and this ownership should result in solutions that are
more sustainable than those imposed by others [91].
REDe means network in Portuguese and Spanish – and
is a shared and open resource centre, where researchers
and health workers can access tools, resources and sup-
port, enabling better and more research in the region.
REDe operates both online and in the regions. Table 3
summarizes the initiatives further arising from
ZikaPLAN. Within these regions, REDe has local coor-
dinators embedded into research teams. Through this
regional programme, there have been workshops and
regional training efforts, which are supported through
the online platform, thus strengthening the impact and
need for sustainability. E-learning courses have also
been developed. The facilities of REDe will be used to
maximize the transfer of research into practice by sum-
marizing the research output and by hosting the tools,
resources, guidance and recommendations generated
by our consortium. This will ensure better visibility
and dissemination of our research methods and find-
ings in addition to long-term knowledge transfer
beyond the funding period. Table 3 summarizes some
websites that post-ZikaPLAN created materials.
To maximize our output, we built up a governance
structure together with ZIKAlliance and ZIKAction
with a reciprocal clinical monitoring platform, a joint
quality assurance programme for the laboratory
Table 3. Web-based information that ZikaPLAN has made publicly available.
Website What is the website about! URL
REDe REDe is an international network focused on building research capacity and
preparedness to tackle emerging infectious disease outbreaks in Latin
America and Caribbean.
https://rede.tghn.org/
Global Birth Defects The Global Birth Defects website is an initiative by the International Committee
for Congenital Anomaly Surveillance Tools to provide specific and pragmatic
resources that can improve surveillance systems and research projects in
low-resource communities and areas where congenital anomaly diagnosis
expertise is scarce.
https://globalbirthdefects.tghn.org/
Brain Infections Global Improving the Management of Acute Brain Infections https://braininfectionsglobal.tghn.org/
Global Vector Hub The Global Vector Hub is an open access, interactive resource that not only has
the capacity to transform vector research and vector control programmes,
but also revolutionise our preparedness and ability to respond quickly and
effectively to vector-borne disease outbreaks, around the world.
https://www.lshtm.ac.uk/research/cen
tres-projects-groups
/globalvectorhub
IGOS
International Guillain-Barré
syndrome outcome
study
The study aims to identify clinical and biological determinants and predictors of
disease course in Guillain-Barré syndrome.
https://gbsstudies.erasmusmc.nl/
IGOS-Zika The International Zika virus related Guillain-Barré syndrome Outcome Study
(IGOS-Zika)
https://igoszika.erasmusmc.nl/
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diagnostics, and established principles of governance
and data sharing, all explicitly described in two joint
work packages. We set up common bodies for the
management of the scientific programme, including
a common Scientific Advisory Board, a common
Ethics Advisory Committee, a Communication
Oversight Board, and cross-consortia working groups.
Outlook
Our consortium will further capitalize on the plat-
forms established and the experience gained through
this urgent ZIKV research response, in order to
evolve into a network capable of rapidly launching
a research response to future severe infectious out-
breaks caused by emerging pathogens with pandemic
potential or potential to cause significant damage to
health and socioeconomic wellbeing in the region.
Our initial research platform will be further devel-
oped through a comprehensive ‘inter-epidemic’
action plan addressing and fine-tuning the response
to any obstacles identified during the ZIKV research
response (e.g. resolving regulatory and other bottle-
necks, development of adaptable study protocols,
strengthening ICT infrastructure for communication
and information exchange, developing a training pro-
gramme to enhance the local partners’ capacity for
laboratory and clinical research, developing
a communication strategy for patient and public
engagement, etc.); as outlined in the original EU call
for Zika research. A comprehensive data-
management framework allowing the standardized
collection, storage, analysis, and sharing of data is
being implemented together with the other Zika con-
sortia for our clinical cohort studies under the gui-
dance of WHO [13]. Additionally, we are working
towards a sustainability strategy and business plan
that would enable the continuation of the network
beyond the timeline of the EU grant. To this end,
ZikaPLAN is now part of the European Clinical
Research Alliance on Infectious Diseases (ECRAID:
https://www.jpiamr.eu/kick-off-ecraid-the-european-
clinical-research-alliance-on-infectious-diseases/),
another EU funded consortium to pro-actively
address the sustainability of infectious diseases net-
works to combat the impact of newly emerging
pathogens and enhance epidemic preparedness. The
project’s vision is to establish a coordinated and per-
manent infrastructure for research on arboviral dis-
eases in the Americas. The vision is to become a self-
sustaining, permanent, single access ‘go-to-network’
for arboviral diseases, with a common research
agenda, organizational structures and processes,
thereby harvesting synergies across the networks.
Ongoing funding will be challenging. However, as
important as the ad-hoc emergency driven EU fund-
ing was for Zika, it would be a shame if all the efforts
and networks would dissolve after the ending of the
4-year project, thus preventing the sustained impact
of the knowledge and infrastructures developed. If
and when new arboviral outbreaks emerge such as
Ross river [92], yellow fever [93], chikungunya [94]
or Mayaro [95], new ad-hoc networks would need to
be established with the inherent risk of inefficiencies,
lack of synergies and predictable delays. Therefore,
the EU and other funding agencies need to start
thinking about funding mechanisms to ensure the
sustained impact of the knowledge and infrastruc-
tures developed through the recently funded three
Zika consortia, ZikaPLAN, ZIKAlliance and
ZIKAction, in order to quickly respond to new arbo-
viral outbreaks. True transparent research partner-
ships are needed between Europe and Latin
America, and not just parachutists [96]. We need
not only bilateral but global research partnerships
that are based on trust, mutual benefit and sharing,
and are able to respond rapidly leveraging upon
already existing structures and networks.
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